Impact of Contraceptives on Cervico-Vaginal Mucosa

Inclusion Criteria:

• Age 18 to 50 years, inclusive
• In general good health without any significant systemic disease and with an intactuterus and cervix.
• History of Pap smears and follow-up consistent with standard, local clinical practiceor willing to undergo a Pap smear at Visit 1
• Willing to give voluntary consent and sign an informed consent form
• Willing and able to comply with protocol requirements, including acceptingrandomization to study contraceptive products
• If currently on a contraceptive product, willing to go off products and use condomsfor birth control for a specified time
• If in a relationship, must be with a partner who is not known to be HIV positive andhas no know risk of sexually transmitted infections (STIs)

Exclusion Criteria:

• Positive pregnancy test or plans to become pregnant during the course of the study
• Currently exclusively breastfeeding or planning to exclusively breastfeed during thecourse of the study
• Less than six weeks from a delivery of an infant greater than 20 weeks gestation
• Use of DMPA in the past 4 months
• Clinical signs and symptoms of menopause
• Current WHO or CDC medical eligibility criteria level 3 or 4 for any contraceptiveproduct to which a participant could receive at the clinical site
• History of sensitivity/allergy to any component of the study product, topicalanesthetic, or to both silver nitrate and Monsel's solution
• Current infection with Trichomonas vaginalis (TV), Neisseria gonorrhea (NG), Chlamydiatrachomatis (CT)
• Current positive test for HIV
• History of a pulmonary embolus or deep vein thrombosis
• Chronic or acute vulvar or vaginal symptoms (pain, irritation, spotting/bleeding,discharge, etc)
• Known blood disorder, eg. von Willebrands disease, that could lead to prolonged orcontinuous bleeding with biopsy
• Chronic use systemic corticosteroids, antibiotics, antimycobacterials, anticoagulantsor other drugs known to prolong bleeding and/or promote clotting, antifungals, orantivirals or antiretrovirals.
• Current or anticipated chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)or acetaminophen for the duration of the study
• Participation in any other investigational trial with use of a drug/device within thelast 30 days or planned participation in any other investigational trial with use of adrug/device during the study
• Abnormal finding on laboratory or physical examination or a social or medicalcondition in which, in the opinion of the investigator, would make participation inthe study unsafe or would complicate interpretation of the data